KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Enterprise Value (2016 - 2025)

Rigel Pharmaceuticals has reported Enterprise Value over the past 16 years, most recently at -$155.0 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$155.0 million for Q4 2025, down 100.4% from a year ago — trailing twelve months through Dec 2025 was -$155.0 million (down 100.4% YoY), and the annual figure for FY2025 was -$155.0 million, down 100.4%.
  • Enterprise Value for Q4 2025 was -$155.0 million at Rigel Pharmaceuticals, down from -$137.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for RIGL hit a ceiling of -$39.3 million in Q1 2021 and a floor of -$155.0 million in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$77.2 million (2024), compared with a mean of -$87.7 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 58.98% in 2021 and later plummeted 173.27% in 2022.
  • Rigel Pharmaceuticals' Enterprise Value stood at -$125.0 million in 2021, then skyrocketed by 53.42% to -$58.2 million in 2022, then rose by 2.19% to -$56.9 million in 2023, then tumbled by 35.81% to -$77.3 million in 2024, then plummeted by 100.4% to -$155.0 million in 2025.
  • The last three reported values for Enterprise Value were -$155.0 million (Q4 2025), -$137.1 million (Q3 2025), and -$108.4 million (Q2 2025) per Business Quant data.